Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36655300/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: In adults with overweight/obesity, semaglutide 2.4 mg improved short- and longer-term control of eating associated with substantial weight loss.
Share
Semaglutide treatment attenuates vessel remodelling in ApoE−/− mice following vascular injury and blood flow perturbation
Source : https://www.sciencedirect.com/science/article/pii/S2667089522000165?via=ihub
Randomized clinical studies have shown a reduction in cardiovascular outcomes with glucagon-like peptide 1 receptor agonist (GLP-1RA) treatment with t...
Conclusions: Semaglutide treatment reduced vessel remodelling following electrical injury and blood flow perturbation in an atheroprone mouse model. This effect appears to be driven by anti-inflammatory and -proliferative mechanisms independent of GLP-1 receptor-mediated signalling in the resident vascular cells. This mechanism of action may...
Share
Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
Obesity is a major health problem worldwide resulting in numerous health conditions such as heart disease, stroke, type 2 diabetes (T2D), and certain types of cancer which are among the...
Conclusions: We assessed the use of oral and subcutaneous semaglutide in our article. Most of the studies included demonstrated a positive effect of semaglutide for obesity treatment. Some studies also revealed a dose-dependent effect of the therapy in those with poorly controlled diabetes. Hence, the result seems to be overwhelmingly in favor...
Share
Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment - International Journal of Obesity
Source : https://www.nature.com/articles/s41366-023-01254-z
Glucagon-like Peptide-1 receptor agonists (GLP-1 RA) and metabolic and bariatric surgery (MBS) both improve cardiovascular outcomes in patients with severe obesity and type-2 diabetes (T2D). The aim of the present...
Conclusion: In this matched cohort study, MBS was associated with lower risk for MACE compared to treatment with early GLP-1 RA in patients with T2D.
Share
Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes
Source : https://www.sciencedirect.com/science/article/abs/pii/S0003426623000045?via=ihub
Glucagon-like peptide-1 (GLP-1) receptor agonists currently occupy a privileged place in the management of type-2 diabetes (T2D). Dual glucose-depende...
Relevance: Glucagon-like peptide-1 (GLP-1) receptor agonists currently occupy a privileged place in the management of type-2 diabetes (T2D). Dual glucose-dependent insulinotropic polypeptides (GIP/GLP-1) have been recently developed.
Share